Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers

Emerging evidence suggests a role of receptor activator of nuclear factor κB (RANK)/RANK ligand (RANKL) signaling in breast cancer development. Lower osteoprotegerin (OPG) levels, the endogenous decoy receptor for RANKL which competes with RANK for binding of RANKL, has been reported among BRCA muta...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Odén, Lovisa, Akbari, Mohammad, Zaman, Tasnim, Singer, Christian F., Sun, Ping, Narod, Steven A., Salmena, Leonardo, Kotsopoulos, Joanne
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2016
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5349945/
https://ncbi.nlm.nih.gov/pubmed/27893411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13417
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares